Sleep, cognition and hormone questions
Several familiar claims point to a different compound, a different outcome or an anecdote.
Does sermorelin improve sleep?
People describe deeper sleep and vivid dreams in community accounts about sermorelin. CJC-1295 discussions contain similar stories, mixed with fatigue or drowsiness in other accounts. Those are anecdotal reports, not clinical evidence; the accounts cannot establish how often an effect occurs or which compound caused it.
A measured sleep outcome would add evidence beyond the known biological connection between GH and sleep. The adult studies discussed on the sermorelin page chiefly tracked hormone responses. A recurring story and a measured sleep outcome deserve different levels of confidence.
The tesamorelin cognition study
The trial of 152 older adults, including 66 with mild cognitive impairment used tesamorelin. At 20 weeks it reported a favorable effect on cognition (P=0.03), including executive function (P=0.005), with IGF-1 up 117% and body fat down 7.4%.
That study often appears in broad discussions of GHRH analogues, which makes the compound name easy to lose. Tesamorelin gets the credit for that particular result, with the trial's population and time limit attached. It establishes no general cognitive benefit for sermorelin or CJC-1295.
Interpreting an IGF-1 increase
It establishes a response to stimulation. The CJC-1295 serum protein experiment treated other protein changes as potential markers of that response. Clinical benefit would involve an outcome such as growth, function or a defined anatomical change.
For a concrete comparison, the older-men sermorelin study followed hormone levels over 14 days, while the HIV tesamorelin trial measured internal fat deposits. IGF-1 alone leaves the growth, fat and functional questions open.
Adult wellness regimens
CJC-1295 has no approved human indication or established wellness regimen. Large, long-term trials supporting adult anti-aging use of sermorelin are absent. The clinical editorial questioning secretagogues for aging addresses precisely that gap.
Personal dosing guidance would need a clinical basis these trials cannot supply. Individual medical decisions require qualified clinical care. The site has no prescribing service, and the tesamorelin approval discussion concerns a specific HIV-associated indication.
How long do the effects last?
The relevant clock depends on the measurement. CJC-1295 can leave IGF-1 above baseline for days; tesamorelin-associated visceral fat reductions reversed after discontinuation. These observations come from different molecules, populations and study designs. A duration for one cannot be imported into the other.
Without a named outcome, the duration has no clear subject. The comparison page lays those outcomes alongside the compound names.